Tesofensine
Tesofensine
Also known as: NS2330, Tesomet
Overview
Key Facts
Primary Goal: A triple monoamine reuptake inhibitor originally developed for neurodegenerative diseases that was repurposed for obesity after significant weight loss was observed in clinical trials
A triple monoamine reuptake inhibitor originally developed for neurodegenerative diseases that was repurposed for obesity after significant weight loss was observed in clinical trials. Tesofensine suppresses appetite and increases thermogenesis through enhanced norepinephrine, dopamine, and serotonin signaling. Half-Life ~200-300 hours Typical Dose 0.25–1 mg Frequency Once daily (oral) Cycle Length 12-24 weeks under medical supervision
Dosing Information
Half-Life
~200-300 hours
Typical Dose
0.25–1 mg
Frequency
Once daily (oral)
Cycle Length
12-24 weeks under medical supervision
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Phase 2 trials demonstrated that tesofensine 0.5 mg produced approximately 12.8% body weight loss over 24 weeks, roughly double that of existing anti-obesity medications at the time. Phase 3 trials (TESORA) are ongoing in several countries. The compound also showed improvements in metabolic parameters including HbA1c and lipid profiles. Cardiovascular safety monitoring remains a key focus.
Frequently Asked Questions
Common questions about Tesofensine
UK-Specific Information
Exclusive data points and guidance for UK residents using Tesofensine
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.